Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$587.9 million.

  • Avidity Biosciences' Cash from Investing Activities fell 2187.19% to -$587.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$309.4 million, marking a year-over-year increase of 5812.86%. This contributed to the annual value of -$854.2 million for FY2024, which is 55672.41% down from last year.
  • Per Avidity Biosciences' latest filing, its Cash from Investing Activities stood at -$587.9 million for Q3 2025, which was down 2187.19% from $185.5 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Cash from Investing Activities peaked at $185.5 million during Q2 2025, and registered a low of -$587.9 million during Q3 2025.
  • In the last 5 years, Avidity Biosciences' Cash from Investing Activities had a median value of -$17.6 million in 2022 and averaged -$79.1 million.
  • The largest annual percentage gain for Avidity Biosciences' Cash from Investing Activities in the last 5 years was 146650.0% (2022), contrasted with its biggest fall of 3332380.95% (2022).
  • Avidity Biosciences' Cash from Investing Activities (Quarter) stood at -$84.1 million in 2021, then skyrocketed by 90.76% to -$7.8 million in 2022, then skyrocketed by 757.05% to $51.0 million in 2023, then tumbled by 225.73% to -$64.2 million in 2024, then tumbled by 816.17% to -$587.9 million in 2025.
  • Its last three reported values are -$587.9 million in Q3 2025, $185.5 million for Q2 2025, and $157.2 million during Q1 2025.